Osteoporosis

Continued doses of denosumab reduced the incidence of diabetes by more than 1000 patients compared to an initial dose alone.

According to the FDA review, patients with CKD receiving denosumab for osteoporosis who are on dialysis or have CKD-MBD are at the highest risk of severe hypocalcemia.

Ten quiz questions to assess your knowledge on common osteoporosis treatments.

The lower a person’s T-score, the lower the bone density.

Patient education is a critical component of helping patients manage this common chronic condition.

The new drug application for PF708 was submitted under the 505(b)(2) regulatory pathway with teriparatide injection as the reference drug.

Amgen is indicated to treat osteoporosis in postmenopausal women at high risk for fracture.

Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Top news of the day from across the health care landscape.

Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.

Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.

Top news of the day across the health care landscape.

Abaloparatide and teriparatide are the only anabolic agents approved by the FDA for women with osteoporosis at high-risk of fragility fractures.

Persistent use of osteoporosis medications was associated with reduced risk of fracture and significantly lower total healthcare costs, a recent analysis of Medicare claims data found.

The United States Preventive Services Task Force (USPSTF) updated its 2011 recommendation about osteoporosis screening.

Officials with the FDA have approved the use of denosumab (Prolia, Amgen) for the treatment of glucocorticoid-induced osteoporosis (GIOP).

Patients with glucocorticoid-induced osteoporosis on glucocorticoid therapy who received denosumab (Prolia) had greater gains in bone mineral density in a phase 3 trial.

Patients with glucocorticoid-induced osteoporosis on glucocorticoid therapy who received denosumab (Prolia) had greater gains in bone mineral density in a phase 3 trial.

The United States Preventive Services Task Force (USPSTF) has issued an updated draft recommendation statement on osteoporosis screening to prevent fractures.

This year, the FDA is on pace to approve about 38 new medications. Here is a look at 6 of these.

Some diabetes drugs may impact bone metabolism and strength.

Romosozumab is being investigated to treat postmenopausal women with osteoporosis.

Tymlos, an injection that treats postmenopausal women with osteoporosis, may incrase the risk of osteosarcoma.

Patients seeking treatment with the same drugs may face different out-of-pocket costs.

Bone turnover markers could tell a physician whether or not a patient is adhering to oral bisphosphonates.

In pharmacy school, I was taught to see if there was a cause when I learned of a patient?s adverse reaction, because if I?m treating the problem without removing the cause, the problem will still persist. In this situation, I couldn?t remove the cause. If I were to request that the doctor stop prescribing the calcium supplements, the elderly patient would be at higher risk for osteoporosis. If I can?t remove the cause, what can I do in this type of situation?

Abaloparatide can prevent bone fractures in postmenopausal women with osteoporosis.

Development of odanacatib has been discontinued, and regulatory approval will not be sought.

Approximately 14% of women who took calcium supplements developed dementia.